mKRAS-VAX vaccine shows promise in preventing pancreatic cancer
In a phase 1 trial at Johns Hopkins, the mKRAS-VAX vaccine demonstrated durable immune responses in 90% of 20 high-risk individuals, with none developing pancreatic cancer after 16.5 months. This synthetic peptide vaccine targets specific KRAS mutations linked to pancreatic cancer, aiming for early interception rather than treatment.
A phase 1 trial at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University has produced encouraging results for mKRAS-VAX, an off-the-shelf synthetic peptide vaccine designed to target mutant KRAS in pancreatic cancer. The study followed 20 high-risk participants who were genetically predisposed to pancreatic ductal adenocarcinoma (PDAC) and showed radiographic evidence of pancreatic lesions. Of these individuals, 90% developed durable tumor-specific T-cell responses, and none developed pancreatic cancer during a median follow-up period of 16.5 months. These findings suggest the vaccine could play a role in preventing the onset of pancreatic cancer in those at higher risk.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Priya reports on breakthroughs that change lives, big and small.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
